New Zealand has experienced an epidemic of predominantly serogroup B meningococcal disease during the past decade. In a prospective study, we treated adults (age, 115 years) with meningococcal disease with intravenous benzyl penicillin (12 MU [7.2 g] per day) for 3 days. Sixty-one adults with suspected meningococcal disease were consecutively admitted during the 33-month period; 3 patients were excluded. The 58 patients had a mean age ‫ע(‬ standard deviation [SD]) of years (median, 21 years; range, 15-70 years). 27.9 ‫ע‬ 14.5
Despite there being 150 years of experience with antimicrobial therapy for meningococcal disease, the optimal duration of treatment remains uncertain. In 1944, Rosenberg and Arling [1] reported recovery in 64 of 65 patients with cerebral fever due to meningococci treated with penicillin (0.12 MU q.d. im or continuous iv infusion, as well as 0.01 MU [6 mg] intrathecally for 8-48 h). Subsequent reports [2, 3] described no better outcomes with longer courses of treatment but advised that a minimum of 7-10 days of treatment should be given. Most authorities continue to recommend у7 days of treatment [4, 5] . It is unclear why these recommendations for increased duration became established.
Shorter courses of treatment (р5 days) have been used for decades in the developing world [6] [7] [8] [9] [10] [11] [12] , and uncontrolled studies [13--17] from developed countries have shown that patients treated with shorter courses of penicillin have similar outcomes when compared with those receiving у7 days of treatment. Similarly, a number of prospective studies of bacterial meningitis, including meningococcal meningitis, in children [18] [19] [20] that have compared short-course treatment with standard longer courses have shown no difference in outcome.
For 130 years, we have been treating adults with meningococcal disease with 4-5 days of benzyl penicillin. We have never seen a relapse [14, 17] . A prolonged epidemic of serogroup B disease in New Zealand during the past decade has enabled us to extend our experience of short-course treatment by conducting a prospective observational study of 3-day treatment with benzyl penicillin for meningococcal disease in adults. 
METHODS
We enrolled all adults (age, 15 years) consecutively admitted to Auckland Hospital (Auckland, New Zealand) from April 1998 through December 2000 with a diagnosis of meningococcal disease. Collected information included patient demographic characteristics, clinical findings at admission, laboratory data, prehospitalization and inpatient antibiotic treatment received, disease complications, and outcome. The laboratory data included neutrophil and platelet count at hospital admission; findings of blood and CSF studies; CSF WBC count and differential, protein level, and glucose level; CSF Gram stain findings and CSF and blood culture results; and serotypes of Neisseria meningitidis; and the MICs of penicillin for the isolates. The MIC was determined using Etest (AB Biodisk). No interpretative standards exist for susceptibility testing of N. meningitidis, so we applied the interpretative standards for Neisseria gonorrhoeae [21] : isolates with an MIC of р0.06 mg/L were considered to be susceptible to penicillin, those with an MIC of 0.12-1.0 mg/L had reduced susceptibility to penicillin, and those with an MIC of у2.0 mg/L were resistant to penicillin. An in-house PCR method was used with primers described elsewhere [22] .
Benzyl penicillin was administered intravenously at a dose of 2.0 MU (1.2 g) every 4 h for 3 days, for a total of 18 doses. All patients were examined by the Infectious Diseases Service shortly after admission and were seen daily until discharge. After discharge from the hospital, patients were examined by the Infectious Diseases Service if there was clinical concern; if not, they were followed up by their general practitioner or seen at an outpatient clinic.
A case was defined as confirmed or probable meningococcal disease [23] . Confirmed cases involved clinically compatible illness with у1 of the following characteristics or events: isolation of N. meningitidis from a sample of an otherwise sterile body site; a positive PCR test result for CSF, blood, serum, or an appropriate tissue biopsy specimen; or detection of gramnegative intracellular diplococci in CSF. Probable cases involved clinically compatible illness with characteristic rash, with or without the isolation of N. meningitidis from a throat culture. Standard definitions for systemic inflammatory response syndrome, severe sepsis, and septic shock were used [24] . Complications were classified as "major" or "minor," as we have defined elsewhere [17] .
RESULTS
Sixty-one patients with presumptive meningococcal disease were admitted to the hospital during the 33-month period. Three patients were excluded from the study; 2 patients did not meet the case definition for meningococcal disease, and the third patient received 5 days of treatment with ceftriaxone because of a concurrent urinary tract infection.
The patients' demographic characteristics, presenting features, and laboratory investigation findings are shown in table 1, and their microbiology data are shown in table 2. Thirtyfive (60%) of the 58 patients in our series had a CSF sample examined, and the findings were abnormal for 27 (77%). Fourteen patients (24%) received antibiotics before hospitalization (9 had received benzyl penicillin and 5 had received amoxycillin).
Forty-four patients had confirmed and 14 had probable meningococcal disease. Figure 1 illustrates the manner in which the confirmed cases met the definition.
The geometric mean MIC of penicillin for all isolates was 0.05 mg/L. The MIC 50 and MIC 90 were 0.06 mg/L and 0.125 mg/L, respectively. Four (12%) of the 34 isolates had reduced susceptibility to penicillin (MIC, 0.12-1.0 mg/L), but no isolates were resistant.
All 58 patients received benzyl penicillin. Thirteen patients (22%) received additional antibiotics during the first 24 h of hospitalization: 9 patients received a single dose of ceftriaxone, 1 received amoxicillin, 1 received vancomycin, 1 received ceftriaxone and flucloxacillin, and 1 received vancomycin, ceftriaxone, and flucloxacillin. Fifty-seven patients received 12 MU (7.2 g) of penicillin per day, and 1 patient received 8 MU (4.8 g) per day. Thirty-two patients (55%) were admitted to the Excluding the 3 patients who died within the first 24 h of hospitalization, the mean length of treatment (‫ע‬SD) was days. Two patients received !3 days of treatment. 3.0 ‫ע‬ 0.5 One patient received only 7 doses of benzyl penicillin-just over 1 day of treatment. She had presented with a 1-week history of fever and a petechial rash but no symptoms of meningitis. An alternate diagnosis was thought to be more likely, and her treatment was stopped. However, N. meningitidis serogroup B was isolated from a throat culture, and PCR of a skin biopsy specimen from a petechial lesion was positive for N. meningitidis DNA. The other patient discharged herself, against medical advice, after receiving 8 doses of benzyl penicillin. She returned to hospital 2 days later and was observed for 2 more days without additional antibiotic therapy. Four patients received 13 days of treatment: 1 patient received treatment for 3.5 days, 2 received treatment for 4 days, and 1 patient received treatment for 5 days.
No patients relapsed. Forty-six patients (79%) were followed up by their general practitioner or at an outpatient clinic, and 7 (12%) were lost to follow-up. The mean length of follow up (‫ע‬SD) was months. 23.9 ‫ע‬ 14.7 Five patients died. Three died on the day of presentation, 1 died on day 3 of unresolved septic shock with multiple cerebral infarctions (while still receiving benzyl penicillin), and 1 died of multiple-organ failure on day 15, without reculture of N. meningitidis from any site. All 5 patients who died presented with fulminant meningococcal disease. The only other major complication was acute renal failure, for which the patient later received a renal transplant. Nineteen patients had у1 minor complication: joint effusions, in 13 patients; sensorineural hearing loss, in 3; myocarditis, in 2; focal cranial nerve lesion, in 1; peripheral nerve lesion, in 1; and skin and soft-tissue ischemic lesions, for which conservative treatment was administered, in 1. No joint effusions were aspirated. No additional complications were diagnosed at follow-up. All patients with complications (excluding those who died) received exactly 3 days of treatment. The mean length of hospital stay (‫ע‬SD) for patients discharged alive was days (median, 4 days; 5.4 ‫ע‬ 5.4 range, 2-40 days).
DISCUSSION
We prospectively treated 58 consecutive adult patients with meningococcal disease of all degrees of severity with 3 days of intravenous benzyl penicillin. Some patients also received у1 dose of other antimicrobial agents because of diagnostic uncertainties in the first 24 h of hospitalization, and others received 1 dose of an antibiotic before hospitalization. This is clinical reality and does not detract from these findings. Three of the 5 deaths occurred р24 h after hospitalization, which is a consistent theme for this disease [25] . Provided that immediate mortality or morbidity are unaffected, then the duration Downloaded from https://academic.oup.com/cid/article-abstract/37/5/658/311339 by guest on 22 January 2019 of treatment should be determined by the microbiological relapse rate. No patients in our study relapsed.
We recently reviewed short-course treatment for meningococcal disease [26] and found 9 studies from developed countries from 1974 through 1995. Some of these studies compared short courses with longer courses of antibiotic therapy. One study [12] used only 2 days of treatment with ceftriaxone for patients with less-severe forms of meningitis. No relapses of meningococcal disease were recorded in any of these studies [26] , regardless of the length of treatment. In studies in which meningitis was the focus of interest, relapse of meningitis due to N. meningitidis was extremely rare [2, 27] .
In our recent review [26] , 19 of 278 patients treated with short-course treatment died, for an overall mortality rate of 6.8%, similar to the mortality rate in our study group of 8.6%. Mortality rates of 5%-10% are typical, despite appropriate and early intervention [25, 28] . The mortality rate for patients with fulminant meningococcal disease is high [25] , and one-half of these patients die within the first 24 h of hospitalization. Death at a later stage of illness is still clearly determined by the early course of the disease. In New Zealand, as in some other countries [29, 30] , it is currently recommended that general practitioners administer parenteral penicillin to all patients with suspected meningococcal disease before hospital admission [23] . In our series, 14 patients (24%) received antibiotics before admission to hospital, and none of these patients died.
Historically, invasive meningococcal disease has been classified into 4 groups: bacteremia without sepsis, meningococcemia without meningitis (i.e., fulminant meningococcal sepsis), meningitis with or without meningococcemia, and meningoencephalitis [3] . We found that classifying cases into these groups of clinical findings alone was extremely difficult. An early study of meningococcal meningitis [31] reported that headache, confusion, and neck stiffness occurred in fewer than one-half of patients, and most series that involve patients with acute bacterial meningitis include only those who have undergone a CSF examination. Regardless of our inability to neatly classify our cases into these groups, we saw patients with all degrees of severity: 19 patients (33%) had severe sepsis, and 12 (21%) had septic shock [24] . It is important to emphasize that all patients in this study received 3 days of penicillin treatment, regardless of symptoms and degree of severity at presentation.
Penicillin has long been recognized as the agent of choice for the treatment of meningococcal disease. The dose of benzyl penicillin we used is lower than the usual recommended dose [5] , but this dose has been used at Auckland Hospital and many other New Zealand hospitals for 140 years. We assume that dosages much lower even than our routine 12 MU (7.2 g) per day in the earliest study [1] drove this initial, now historical local decision, which has been perpetuated by successive generations of New Zealand infectious diseases physicians. The similarity of local outcomes to those reported elsewhere and the complete absence of relapse demonstrates its efficacy. These data also argue that the usual recommended doses are unnecessarily large. Relative resistance to penicillin is now seen [32] [33] [34] [35] . Four of our patients' isolates had reduced susceptibility to penicillin. Of the 4 patients, 1 died of fulminant meningococcal disease, and the other 3 were cured. In other studies with small numbers of subjects, treatment with conventional doses of penicillin has remained effective against strains with reduced susceptibility [34, 36] . We acknowledge that increasing resistance could change this.
In summary, no patients relapsed after receiving 3 days of treatment with intravenous benzyl penicillin for meningococcal disease, no patient required joint aspiration, and 4 of the 5 deaths occurred during the 3 days of benzyl penicillin treatment. Meningococcal disease remains a major life-threatening disease in both developing and developed countries. Even with prompt recognition and appropriate treatment, the mortality rate is still up to 10%. Our experience shows that shortening the length of treatment to 3 days does not influence outcome. Shortening the duration of the antibiotic course will reduce the complications associated with unnecessary antibiotic use and also reduces the length of hospitalization, allowing for cost savings without unfavorably affecting the clinical outcome.
